REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Protocols
12

5-Amino-1MQ Administration Tips and Schedule

Brook Hopkins·about 1 month ago
Tips and tricks I have picked up from running 5-Amino-1MQ over the past few months. These are the practical details that nobody seems to talk about in the typical protocol discussions. Reconstitution: aim the stream of bacteriostatic water at the vial wall, not directly onto the powder. Let it run down slowly. Then set the vial in the fridge for 10 minutes. Come back and gently swirl. This gives you the clearest solution with minimal foaming. Injection technique: pinch a fold of skin at the injection site, insert the needle at about 45 degrees, inject slowly over 5-10 seconds, and hold for another 5 seconds before withdrawing. This minimizes leakage and irritation. Storage: I keep my reconstituted vials in the back of the fridge where the temperature is most stable. Avoid the door shelves where temperature fluctuates every time you open the fridge. Tracking: I use a simple spreadsheet with columns for date, time, dose, injection site, side effects, and a 1-10 subjective score. Looking at trends over weeks is far more valuable than obsessing over day-to-day variation. Schedule consistency: I set a daily alarm. Dosing at the same time every day has made a noticeable difference compared to when I was more casual about timing.

Comments (5)

Bailey EllisDEMO·about 1 month ago

I have been stacking 5-Amino-1MQ with another peptide for the last 8 weeks and the combination has been notably better than either alone in my experience. The synergy makes sense given their complementary mechanisms. Happy to share my specific protocol if anyone is interested.

2
Beau FreemanDEMO·about 1 month ago

Real talk: 5-Amino-1MQ worked well for me but the cost is significant. For anyone considering it, I would suggest doing a proper cost-benefit analysis first. Calculate the total cost for a full protocol and honestly assess whether the expected benefits justify that investment.

3
Lake HaleDEMO·about 1 month ago

Interesting data. My 5-Amino-1MQ experience was somewhat different — I noticed effects earlier than you did, probably because I started at a higher initial dose. Trade-off was more pronounced side effects in week 1 that resolved by week 2. Neither approach is wrong, just different risk-reward profiles.

4
Tatum BennettDEMO·about 1 month ago

This thread has been incredibly helpful for understanding 5-Amino-1MQ. I have been on the fence about starting for months and reading detailed real-world experiences like these has been more useful than any blog post or article I have found. The fact that most reports here are moderate rather than extreme actually increases my confidence.

5
Evan HewittDEMO·about 1 month ago

One thing I wish more 5-Amino-1MQ discussions covered is the discontinuation experience. What happens when you stop? In my case, the benefits gradually faded over about 3-4 weeks after stopping. Sleep was the first thing to return to baseline. Recovery improvements lasted a bit longer. Worth knowing for planning protocol duration.

6

Sign in to comment.